Q3FY26 Performance Highlights

• Revenues at ₹2,903 million, down 26% YoY, impacted by delayed semaglutide approvals in Canada
• EBITDA at ₹173 million, down 88% YoY, due to lower revenue in the quarter and largely fixed cost base
• Adjusted PAT stood at (₹472) million with adjusted EPS of (₹4.1)
• Effective interest rate (EIR) below 9%, 200bps lower YoY

FY28 Guidance Reaffirmation

• ₹400 million in organic revenue and ₹500 million including recently proposed acquisition, with a ~40% EBITDA margin outlook, subject to shareholder approvals
• Organic business targeting ROCE1 above 50% and Net-to-EBITDA below 1.5x

1. Goodwill and Scheme Intangibles arising from the business combination is excluded from the ROCE calculation as it is not reflective of operating performance in the absence of common control. Capital employed excludes new capital investment in progress.

Bangalore, India, January 23, 2026 - OneSource Speciality Pharma Limited (BSE:544292, NSE: ONESOURCE) today announced its consolidated financial results for the quarter ended December  31, 2025 (Q3FY26).

Financial Highlights (In ₹ million)

Note: Adjusted PAT and Adjusted EPS excludes exceptional items (Q3FY26: ₹71m, Q2FY26: Nil, Q3FY25: ₹1,005m) and scheme related intangible amortisation (Q3FY26: ₹344m, Q2FY26: ₹344m, Q3FY25: ₹355m)

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the performance said, “As previously anticipated, this has been a subdued quarter due to delays in customer approvals in Canada that have prolonged the transition from the MSA to the CSA phase. The inherent demand, however, remains intact with order book continuing to trend upwards. In our nascent biologics segment, we continue to witness strong interest, with another global biosimilar player onboarded and the funnel at a historic high.”